Meng Xiang-Dong, Gao Wei-Qin, Sun Ze
First Ward of Cardiology Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Medicine (Baltimore). 2019 Feb;98(7):e14544. doi: 10.1097/MD.0000000000014544.
Amiodarone and acupuncture (AA) are commonly used to treat cardiac arrhythmia (CA). The objective of this systematic review is to assess the efficacy and safety of AA for patients with CA.
Randomized controlled trials (RCTs) of AA for CC will be searched from 9 databases including PubMed, EMBASE, Cochrane Library, Web of Science, Scopus, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data from inception to February 1, 2019 without any limitations. Two reviewers will independently screen the relevant papers, extract data, and evaluate the risk of bias for each included study. RevMan 5.3 software will be used for meta-analysis. The primary outcome includes arrhythmic episodes (including time and frequency domain parameters). The secondary outcomes consist of health-related quality of life, oxygen saturation, and safety.
The protocol of this proposed study will provide evidence to judge whether AA is an effective treatment for patients with CA.
The findings of this proposed study will summarize the up-to-date evidence of AA for CA.
PROSPERO CRD42019120962.
胺碘酮与针灸（AA）常用于治疗心律失常（CA）。本系统评价的目的是评估AA治疗CA患者的有效性和安全性。
从包括PubMed、EMBASE、Cochrane图书馆、科学网、Scopus、中国生物医学文献数据库、中国知网、维普资讯和万方数据在内的9个数据库中检索自建库至2019年2月1日关于AA治疗CA的随机对照试验（RCT），无任何限制。两名评价员将独立筛选相关论文、提取数据并评估每项纳入研究的偏倚风险。将使用RevMan 5.3软件进行荟萃分析。主要结局包括心律失常发作（包括时域和频域参数）。次要结局包括健康相关生活质量、血氧饱和度和安全性。
本拟开展研究的方案将为判断AA是否为CA患者的有效治疗方法提供证据。
本拟开展研究的结果将总结AA治疗CA的最新证据。
PROSPERO CRD42019120962。
